Principal Financial Group Inc. Has $48,000 Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Principal Financial Group Inc. lessened its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 46.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,408 shares of the biotechnology company’s stock after selling 9,884 shares during the quarter. Principal Financial Group Inc.’s holdings in Anavex Life Sciences were worth $48,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of AVXL. Jupiter Asset Management Ltd. increased its holdings in shares of Anavex Life Sciences by 675.0% during the 1st quarter. Jupiter Asset Management Ltd. now owns 804,642 shares of the biotechnology company’s stock worth $4,096,000 after acquiring an additional 700,812 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Anavex Life Sciences in the fourth quarter valued at $537,000. Vanguard Group Inc. raised its position in shares of Anavex Life Sciences by 1.2% in the first quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company’s stock valued at $22,471,000 after purchasing an additional 54,034 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Anavex Life Sciences by 17.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company’s stock worth $1,184,000 after buying an additional 40,895 shares during the last quarter. Finally, Nwam LLC grew its stake in Anavex Life Sciences by 4.8% in the 1st quarter. Nwam LLC now owns 836,730 shares of the biotechnology company’s stock valued at $4,259,000 after buying an additional 38,437 shares during the last quarter. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Stock Up 7.3 %

Shares of NASDAQ:AVXL opened at $5.70 on Tuesday. Anavex Life Sciences Corp. has a 12-month low of $3.25 and a 12-month high of $10.45. The company’s 50 day moving average price is $5.97 and its two-hundred day moving average price is $4.88. The firm has a market cap of $483.36 million, a PE ratio of -11.40 and a beta of 0.62.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. During the same period in the prior year, the business posted ($0.14) EPS. On average, research analysts expect that Anavex Life Sciences Corp. will post -0.55 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. EF Hutton Acquisition Co. I upgraded shares of Anavex Life Sciences to a “strong-buy” rating in a research report on Monday, July 22nd. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Anavex Life Sciences in a report on Thursday, August 1st.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.